Amgen, a US multinational biopharmaceutical company, announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, Rhode Island (USA) campus. The new plant is the first-of-its-kind in the USA and will use Amgen’s proven next-generation biomanufacturing capabilities.
A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. Next-generation biomanufacturing plants require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions. Within the plant, the equipment is portable, smaller and some components are disposable, which provides greater flexibility and speed when manufacturing different medicines simultaneously. This eliminates costly and complex retrofitting inherent in standard facilities and allows Amgen to respond to changing demands for its medicines with increased agility, ultimately impacting the speed at which a medicine is available for patients.
Amgen expects to invest up to $200 million in the next-generation manufacturing plant in Rhode Island. The existing Amgen Rhode Island plant was licensed by the U.S. Food and Drug Administration in September 2005 and houses one of the world’s largest mammalian protein manufacturing facilities.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.